Michael A Linden

List of Publications by Year
in descending order

84 papers	1,300 citations	471509 17 h-index	395702 33 g-index
84 all docs	84 docs citations	84 times ranked	2412 citing authors

#	Article	IF	Citations
1	Myeloid Sarcoma Expressing Keratins and Mimicking Carcinomaâ€"Case Report and Literature Review. Laboratory Medicine, 2022, 53, 100-106.	1.2	6
2	Patients without cutaneous Tâ€cell lymphoma frequently harbor <scp>CD4</scp> Tâ€lymphocytes that lack <scp>CD26</scp> and/or <scp>CD7</scp>. Cytometry Part B - Clinical Cytometry, 2022, 102, 412-414.	1.5	2
3	Coreâ€binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. International Journal of Laboratory Hematology, 2021, 43, e19-e25.	1.3	6
4	Interlaboratory Agreement of Antiâ€"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Serologic Assays in the Expedited College of American Pathologists Proficiency Testing Program. Archives of Pathology and Laboratory Medicine, 2021, 145, 536-542.	2.5	6
5	Castleman disease: A single-center case series. International Journal of Surgery Case Reports, 2021, 80, 105650.	0.6	6
6	ZBTB20 regulates WNT/CTNNB1 signalling pathway by suppressing PPARG during hepatocellular carcinoma tumourigenesis. JHEP Reports, 2021, 3, 100223.	4.9	13
7	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Advances, 2021, 5, 2481-2489.	5.2	25
8	Patient and External Quality Assessment Samples Demonstrate Similar Bias Between Manufacturers in Titer of Antibodies to Nuclear Antigens: Implications for Commutability. Archives of Pathology and Laboratory Medicine, 2021, 145, 919-920.	2.5	0
9	Indolent B-Lineage Precursor Populations Identified by Flow Cytometry and Immunohistochemistry in Benign Lymph Nodes. American Journal of Clinical Pathology, 2021, , .	0.7	3
10	Performance of perpendicular drop versus tangent skimming gating of M-protein in proficiency testing challenges. Clinical Chemistry and Laboratory Medicine, 2021, 59, e19-e22.	2.3	3
11	Participation in the College of American Pathologists Laboratory Accreditation Program Decreases Variability in B-Lymphoblastic Leukemia and Plasma Cell Myeloma Flow Cytometric Minimal Residual Disease Testing: A Follow-up Survey. Archives of Pathology and Laboratory Medicine, 2021, 145, 336-342.	2.5	2
12	Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by alloâ€inactivation and ILC2â€mediated tissue repair. American Journal of Transplantation, 2021, , .	4.7	3
13	Long-Term Variability in Immunofluorescence Titer of Antibodies to Nuclear Antigens Observed in Clinical Laboratory Proficiency Testing Surveys. Archives of Pathology and Laboratory Medicine, 2021, 145, 937-942.	2.5	4
14	VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months. American Journal of Clinical Pathology, 2020, 153, 221-228.	0.7	7
15	Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia. Cancer Research, 2020, 80, 458-470.	0.9	46
16	Adult Langerhans histiocytosis with rare BRAF mutation complicated by massive pulmonary embolism. Thrombosis Research, 2020, 193, 207-210.	1.7	1
17	Variability in the Laboratory Measurement of Cytokines. Archives of Pathology and Laboratory Medicine, 2020, 144, 1230-1233.	2.5	18
18	Evolution of clonal dynamics and differential response to targeted therapy in a case of systemic mastocytosis with associated myelodysplastic syndrome. Leukemia Research, 2020, 95, 106404.	0.8	1

#	Article	IF	Citations
19	Phenotypic and Functional Characterization of Multiple Myeloma By Single Cell Mass Cytometry (CyTOF). Blood, 2020, 136, 40-41.	1.4	0
20	CD161 Is Expressed in a Subset of T-Cell Prolymphocytic Leukemia Cases and Is Useful for Disease Follow-up. American Journal of Clinical Pathology, 2019, 152, 471-478.	0.7	6
21	Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer. JAMA Oncology, 2019, 5, 1222.	7.1	19
22	Sarcoid-like Histiocytic Proliferations in Patients With Lymphoma Can Be FDG-avid Concerning for Refractory or Recurrent Disease. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e597-e601.	0.4	3
23	Romiplostim Improves Platelet Recovery after UCB Transplant. Blood, 2019, 134, 1979-1979.	1.4	1
24	Lines of Zahn in the Splenic Vein. Thrombosis and Haemostasis, 2018, 118, 957-958.	3.4	4
25	Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women With Suspected Ovarian Cancer. Laboratory Medicine, 2018, 49, 134-139.	1.2	27
26	Genomics of clonal evolution in a case of essential thrombocythemia. Leukemia and Lymphoma, 2018, 59, 497-500.	1.3	2
27	Chronic liver injury alters driver mutation profiles in hepatocellular carcinoma in mice. Hepatology, 2018, 67, 924-939.	7.3	36
28	Coreâ€binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (Iâ€•CBF) Tj ETQq0 0 0 rgBT /Overloc	2.8	17
29	Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual diseaseâ€negative first complete remission. American Journal of Hematology, 2018, 93, E381-E383.	4.1	3
30	Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica, 2017, 102, 865-873.	3.5	206
31	Green Neutrophilic Inclusions are Frequently Associated With Liver Injury and May Portend Short-Term Mortality in Critically Ill Patients. Laboratory Medicine, 2017, 48, 18-23.	1.2	18
32	Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry. Leukemia and Lymphoma, 2017, 58, 1931-1940.	1.3	17
33	Unusual extramedullary hematopoietic neoplasms in lymph nodes. Human Pathology, 2017, 62, 13-22.	2.0	7
34	Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies. Leukemia and Lymphoma, 2017, 58, 1702-1710.	1.3	10
35	B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry. Human Pathology, 2017, 61, 140-147.	2.0	6
36	Sleeping Beauty Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors. Cancer Research, 2017, 77, 6576-6588.	0.9	40

#	Article	IF	Citations
37	History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission. American Journal of Hematology, 2017, 92, 1032-1036.	4.1	17
38	Anaplastic mast cell sarcoma: a unique pathologic entity in mastocytosis. Leukemia and Lymphoma, 2017, 58, 1515-1517.	1.3	5
39	Standardization of Minimal Residual Disease Testing in Multiple Myeloma. journal of applied laboratory medicine, The, 2017, 2, 118-122.	1.3	1
40	Patients With a History of Chemotherapy and Isolated del(20q) With Minimal Myelodysplasia Have an Indolent Course. American Journal of Clinical Pathology, 2016, 145, 459-466.	0.7	4
41	Encapsulated relapsed FLT3+AML (myeloid sarcoma) and <scp>H</scp>Ã¼rthle cell adenoma presenting in composite: Unlikely partners. American Journal of Hematology, 2016, 91, E505-E506.	4.1	0
42	CLINICAL CHALLENGE. Journal of Zoo and Wildlife Medicine, 2016, 47, 948-951.	0.6	0
43	Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 669-675.	2.0	54
44	Loss of UHRF2 expression is associated with human neoplasia, promoter hypermethylation, decreased 5-hydroxymethylcytosine, and high proliferative activity. Oncotarget, 2016, 7, 76047-76061.	1.8	17
45	Standardized Synoptic Reports for Plasma Cell Neoplasms: Integration of Laboratory and Clinical Data. , 2016, , 143-149.		0
46	Role of Flow Cytometry in Plasma Cell Neoplasms. , 2016, , 101-122.		1
47	The Effect of Measurable Residual Disease at the Time of Allogeneic Hematopoietic Cell Transplantation on Outcomes in Patients with Acute Myeloid Leukemia: A Meta-Analysis. Blood, 2016, 128, 2842-2842.	1.4	0
48	An Innovative Method for Obtaining Consistent Images and Quantification of Histochemically Stained Specimens. Journal of Histochemistry and Cytochemistry, 2015, 63, 233-243.	2.5	10
49	Abnormal immunophenotype of the Tâ€cellâ€receptor beta Chain in follicularâ€helper T cells of angioimmunoblastic Tâ€cell lymphoma. Cytometry Part B - Clinical Cytometry, 2015, 88, 190-193.	1.5	5
50	Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program. Archives of Pathology and Laboratory Medicine, 2015, 139, 1276-1280.	2.5	30
51	In Reply. Archives of Pathology and Laboratory Medicine, 2015, 139, 846-847.	2.5	0
52	Parenchymal infiltration and lymphoma-associated membranoproliferative pattern of glomerular injury: an unusual presentation of mantle cell lymphoma. Clinical Nephrology, 2015, 84 (2015), 173-180.	0.7	6
53	Genetic Signature of Histiocytic Sarcoma Revealed by a Sleeping Beauty Transposon Genetic Screen in Mice. PLoS ONE, 2014, 9, e97280.	2.5	16
54	Utilization of Translational Bioinformatics to Identify Novel Biomarkers of Bortezomib Resistance in Multiple Myeloma. Journal of Cancer, 2014, 5, 720-727.	2.5	20

#	Article	IF	Citations
55	Quality and Adequacy of Bone Marrow Samples Obtained by the 2-Needle Technique: The Minnesota Experience. Archives of Pathology and Laboratory Medicine, 2014, 138, 860-862.	2.5	9
56	Early Diagnosis of Intravascular Large B-Cell Lymphoma: Clues From Routine Blood Smear Morphologic Findings. Laboratory Medicine, 2014, 45, 248-252.	1.2	8
57	Hematopoietic Cell Transplantation for Mantle Cell Lymphoma: Predictive Value of Pretransplant Positron Emission Tomography/Computed Tomography and Bone Marrow Evaluations for Outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 114-121.	0.4	20
58	Stabilization of activation induced cytidine deaminase by bortezomib does not confer increased drug target mutation frequency. Leukemia and Lymphoma, 2014, 55, 220-222.	1.3	0
59	Lethal small bowel necrosis due to aspergillosis during acute promyelocytic leukemia induction. American Journal of Hematology, 2013, 88, 329-332.	4.1	5
60	Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. Bone Marrow Transplantation, 2013, 48, 1415-1420.	2.4	29
61	Burkitt Lymphoma in Pregnancy: Two Cases of Successful Treatment and Continued Fertility; With a Review of the Literature. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, e10-e14.	0.4	2
62	Perigestational Dietary Folic Acid Deficiency Protects Against Medulloblastoma Formation in a Mouse Model of Nevoid Basal Cell Carcinoma Syndrome. Nutrition and Cancer, 2013, 65, 857-865.	2.0	7
63	Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumab. Leukemia and Lymphoma, 2013, 54, 174-176.	1.3	3
64	How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. American Journal of Hematology, 2013, 88, 826-827.	4.1	2
65	Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model. Molecular Cancer Therapeutics, 2013, 12, 1140-1150.	4.1	68
66	Crystallizing Immunoglobulin Presenting as Polychromatic Crystalline Keratopathy: An Unusual Clinical Presentation of Monoclonal Gammopathy of Undetermined Significance (MGUS). Laboratory Medicine, 2013, 44, 344-347.	1.2	0
67	Case study interpretationâ€"New Orleans: Case 4. Cytometry Part B - Clinical Cytometry, 2013, 84, 350-353.	1.5	2
68	Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia, 2013, 27, 2075-2077.	7.2	45
69	Bortezomib Resistance Can Be Reversed by Induced Expression of Plasma Cell Maturation Markers in a Mouse In Vitro Model of Multiple Myeloma. PLoS ONE, 2013, 8, e77608.	2.5	17
70	Bortezomib Is Highly Effective For Pure Red Cell Aplasia After ABO-Incompatible Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 5495-5495.	1.4	0
71	Acute Appendicitis in a Man Undergoing Therapy for Mantle Cell Lymphoma. Case Reports in Hematology, 2012, 2012, 1-4.	0.4	3
72	Hematopoietic and Lymphoid Tissues. , 2012, , 309-338.		7

#	Article	IF	Citations
73	Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia. Experimental Hematology, 2012, 40, 216-227.	0.4	4
74	Autologous and Allogeneic Donor Transplantation for Mantle Cell Lymphoma in Rituximab Era: Impact of Pre-Transplant Burden On Survival.. Blood, 2012, 120, 3092-3092.	1.4	2
75	Utility of Flow Cytometry to Classify Abnormal Plasma Cell Populations in Marrow Samples Collected from Patients with Putative Plasma Cell Neoplasms. Open Journal of Blood Diseases, 2012, 02, 39-45.	0.1	4
76	Factor V Leiden and hepatic artery thrombosis after liver transplantation. Clinical Transplantation, 2006, 20, 132-135.	1.6	17
77	Use of B-Type Natriuretic Peptide Testing in a Community Teaching Hospital 4 Years After Implementation and Agreement of Results with Discharge Diagnoses. Clinical Chemistry, 2006, 52, 767-768.	3.2	1
78	ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-XL transgenic mice. Leukemia Research, 2005, 29, 435-444.	0.8	8
79	Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. Blood, 2004, 103, 2779-2786.	1.4	46
80	Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice. Journal of Clinical Investigation, 2004, 113, 1763-1773.	8.2	84
81	Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice. Journal of Clinical Investigation, 2004, 113, 1763-1773.	8.2	70
82	Targeted Overexpression of Mutant Activated N-ras Leads to Aberrant Plasma Cell Biology.. Blood, 2004, 104, 1416-1416.	1.4	0
83	Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells. Blood, 2003, 102, 2581-2592.	1.4	71
84	Induced Îº Receptor Editing Shows No Allelic Preference in a Mouse Pre-B Cell Line. Journal of Immunology, 2000, 165, 7058-7063.	0.8	6